Market Overview

UPDATE: Oppenheimer Raises PT on Health Management Associates and Reiterates Outperform Rating

Related HMA
Benzinga's Volume Movers
US Stock Futures Rise Ahead Of International Trade Data

Oppenheimer analyst Michael Wiederhorn published a report on Health Management Associates (NYSE: HMA) that reiterated its Outperform rating and raised the price target from $12 to $14.

Oppenheimer reported that, “Our 12-18 month price target of $14 equates to approximately 7X our 2014 EBITDA estimate of $1,001.8M, which is a discount to the historical industry average of 8.5X. We believe this discount is even more conservative when considering it does not include any potential upside to earnings from healthcare reform in 2015 and 2016.”

Shares of Health Management Associates close that $38.56 on Thursday.

Latest Ratings for HMA

DateFirmActionFromTo
Dec 2013Wells FargoDowngradesOutperformMarket Perform
Sep 2013Avondale PartnersDowngradesMarket OutperformMarket Perform
Aug 2013UBSDowngradesBuyNeutral

View More Analyst Ratings for HMA
View the Latest Analyst Ratings

Posted-In: OppenheimerAnalyst Color Price Target Analyst Ratings

 

Related Articles (HMA)

Around the Web, We're Loving...

Get Benzinga's Newsletters